DK1660100T3 - Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler - Google Patents

Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler

Info

Publication number
DK1660100T3
DK1660100T3 DK04764686T DK04764686T DK1660100T3 DK 1660100 T3 DK1660100 T3 DK 1660100T3 DK 04764686 T DK04764686 T DK 04764686T DK 04764686 T DK04764686 T DK 04764686T DK 1660100 T3 DK1660100 T3 DK 1660100T3
Authority
DK
Denmark
Prior art keywords
tumor
formulations
combination
defibrotide
agents
Prior art date
Application number
DK04764686T
Other languages
Danish (da)
English (en)
Inventor
Laura Iris Ferro
Massimo Iacobelli
Paul Richardson
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Application granted granted Critical
Publication of DK1660100T3 publication Critical patent/DK1660100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK04764686T 2003-09-05 2004-08-27 Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler DK1660100T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Publications (1)

Publication Number Publication Date
DK1660100T3 true DK1660100T3 (da) 2008-11-10

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764686T DK1660100T3 (da) 2003-09-05 2004-08-27 Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler

Country Status (23)

Country Link
US (2) US8551967B2 (de)
EP (1) EP1660100B1 (de)
JP (1) JP4671962B2 (de)
KR (1) KR20060061367A (de)
CN (1) CN100490820C (de)
AT (1) ATE399558T1 (de)
AU (1) AU2004269896B2 (de)
BR (1) BRPI0414114A (de)
CA (1) CA2537226C (de)
DE (1) DE602004014787D1 (de)
DK (1) DK1660100T3 (de)
ES (1) ES2308223T3 (de)
IL (1) IL173785A0 (de)
IS (1) IS8334A (de)
IT (1) ITMI20031714A1 (de)
MX (1) MXPA06002489A (de)
NO (1) NO20061402L (de)
PT (1) PT1660100E (de)
RS (1) RS20060154A (de)
RU (1) RU2348413C2 (de)
UA (1) UA83500C2 (de)
WO (1) WO2005023273A1 (de)
ZA (1) ZA200601852B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070120953A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 항암활성을 갖는 제제
EP1872787A1 (de) * 2006-06-27 2008-01-02 Gentium S.p.A. Verwendung von Defibrotide als Heparanasehemmer
EP2103689A1 (de) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetische Phosphodiester-Oligonukleotide und deren therapeutische Verwendungen
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
RU2627177C2 (ru) 2012-06-22 2017-08-03 Джентиум С.Р.Л. Способ определения биологической активности дефибротида, основанный на применении эуглобулина
EP3026122A1 (de) 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
CN112236149A (zh) 2018-04-12 2021-01-15 贾兹制药公司 用于预防和治疗细胞因子释放综合征和与免疫耗竭相关的神经毒性的去纤苷
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
HK1044896A1 (zh) * 1997-04-28 2002-11-08 Burcoglu Arsinur 治疗hiv感染和与之有关的继发感染的方法
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
JP2005503756A (ja) * 2000-12-29 2005-02-10 サビエント ファーマシューティカルズ，インコーポレイティド 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
PL374402A1 (en) * 2002-05-31 2005-10-17 Klinikum Universitaet Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
WO2004003166A2 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
ES2378987T3 (es) 2002-08-06 2012-04-19 Toray Industries, Inc. Remedio o agente preventivo para una enfermedad renal y procedimiento para diagnosticar una enfermedad renal
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
KR20070120953A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 항암활성을 갖는 제제
EP1872787A1 (de) 2006-06-27 2008-01-02 Gentium S.p.A. Verwendung von Defibrotide als Heparanasehemmer
EP1982722A1 (de) 2007-04-16 2008-10-22 Gentium S.p.A. Verwendung von Oligotid zur Behandlung von Nierenerkrankungen

Also Published As

Publication number Publication date
ZA200601852B (en) 2007-06-27
ATE399558T1 (de) 2008-07-15
US8551967B2 (en) 2013-10-08
CN1845746A (zh) 2006-10-11
BRPI0414114A (pt) 2006-10-31
US20060211646A1 (en) 2006-09-21
IS8334A (is) 2006-02-28
ES2308223T3 (es) 2008-12-01
DE602004014787D1 (de) 2008-08-14
ITMI20031714A1 (it) 2005-03-06
KR20060061367A (ko) 2006-06-07
NO20061402L (no) 2006-03-28
MXPA06002489A (es) 2006-06-20
PT1660100E (pt) 2008-10-14
RU2348413C2 (ru) 2009-03-10
AU2004269896A1 (en) 2005-03-17
UA83500C2 (uk) 2008-07-25
EP1660100A1 (de) 2006-05-31
US20140005256A1 (en) 2014-01-02
EP1660100B1 (de) 2008-07-02
CN100490820C (zh) 2009-05-27
WO2005023273A1 (en) 2005-03-17
CA2537226A1 (en) 2005-03-17
CA2537226C (en) 2016-05-03
IL173785A0 (en) 2006-07-05
JP4671962B2 (ja) 2011-04-20
RU2006109210A (ru) 2007-10-10
JP2007504194A (ja) 2007-03-01
RS20060154A (sr) 2008-08-07
AU2004269896B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
PT1411908E (pt) Tratamento de infeccoes da unha com no
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
IL211084A0 (en) Single use module
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
DE60106954D1 (de) Resorcin-derivate
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DK1660100T3 (da) Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler
GT200600520A (es) Agentes antibacterianos
EA200901443A1 (ru) Фунгицидные смеси
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita&#39; antiossidante.
ATE373504T1 (de) Avermectinen oder milbemycine und bis-aryl- derivate enthaltende anthelminthische zusammensetzungen
ECSP066481A (es) Formulaciones que contienen cobre
ATE397861T1 (de) Synergistische zusammensetzungen
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
HRP20090336T1 (hr) Antitumorske kombinacije koje sadrže zamku za vegf i 5-fu ili jedan od njegovih derivata
BR0111785A (pt) Composições e métodos para tratamento de candidìase
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
NO20065791L (no) Asyklovir-formuleringer
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.